Moreover, oridonin downregulated/inhibited the phosphorylation of EGFR and ERK significantly, suggesting that it might be inhibiting the proliferation, invasion, and migration of gefitinib-resistant NSCLC by inhibiting EGFR/ERK/MMP-12 signaling pathways, which made it a potential effective candidate to treat gefitinib-resistant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.